In summary, our present study demonstrates that erythropoietin promotes blood vessel growth (angiogenesis) in vitro and in vivo, which can increase the risk of a potentially serious complication (thrombosis) that can lead to cardiovascular disease and even death, in addition to supporting tumor growth and spread. Here, EPO is linked to cardiovascular disorder.